FORMA Therapeutics, Inc. And Paradigm Announce Molecular Profiling Collaboration For Drug Candidates

ANN ARBOR, Mich. & WATERTOWN, Mass.--(BUSINESS WIRE)--Paradigm and FORMA Therapeutics, Inc. announced today a multi-year partnership to identify predictive response markers and measure pharmacodynamic activity for two of FORMA’s advanced preclinical candidates. Working with Paradigm to assess the potential of molecular markers to predict clinical outcomes will help FORMA accelerate clinical decisions and optimize its new medicines for patients.

Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics stated, “FORMA’s strategy is to pair a thorough understanding of the molecular drivers of tumor growth and survival with our capability to discover ultra-selective drugs against these qualified targets. Our collaboration with Paradigm enables us to efficiently match our drugs with high quality molecular assays to realize a personalized approach to cancer drug development.”

Help employers find you! Check out all the jobs and post your resume.